Acne is a common disease characterised by follicular hyperkeratinisation, bacterial hipercolonisation as well as immune reactions and inflammation. In acne, reactive oxygen species (ROS) may be released from the damaged follicular walls, which could cause the advancement of inflammation in the pathogenesis of the disease. The topical application of antioxidants is a promising approach to support the endogenous antioxidant defence and avoid oxidative injury that may lead to acne. The skin provides a painless and patient-friendly approach for systemic drug administration. Transdermal drug delivery not only improves patient compliance, but also avoids the first-pass effect. The major hurdle to penetration of matter through the skin is provided by an outward layer of the skin, the stratum corneurm (SC). Overcoming this barrier safely and reversibly is a fundamental problem in the field of transdermal drug delivery. Alpha-lipoic acid was utilised as the cosmeceutical active and can be classified in a mixed category of compounds that lie between cosmetics and drugs. Alpha-lipoic acid and its reduced form, dihydrolipoic acid, have been described as the "universal antioxidants" because of their capacity to quench a number of free radicals in both aqueous and lipid environments, their metal-chelating properties and ability to restore other antioxidants from their inactive form. The Pheriod™ system is a new manner of drug delivery aimed at overcoming the barrier function of the skin. It consists of vesicular structures, the sizes of which vary from 200-440 nm. These vesicles, prepared from customised essential fatty acids, were found to advance the efficacy of topically administered compounds. The aim of this study was to determine whether the Pheroid™ delivery system would enhance the transdermal delivery of formulations containing alpha-lipoic acid to the target site by performing Franz cell diffusion studies over a 12 hour period, followed by tape-stripping experiments. The results of the formulations containing Pheroid™ were compared to those of the formulations without Pheroid™. Experimental determination of transdermal flux of the alpha-lipoic acid formulations revealed that Pheroid™ improved the transdermal delivery of alpha-lipoic acid. The average flux of Pheroid™ cream from 0 to 2 hours wass 58.01 ± 6.63 ug/cm2.h. The average flux of Pheroid™ gel from 4 to 12 hours was 22.18 ± 3.33 ug/cm2.h. Tape-stripping experiments proved that the concentrations of alpha-lipoic acid in Pheroid™ cream and cream that remained in the epidermis after application to the skin were 569.10 ug/ml and 764.93 ug/ml respectively. The concentrations of alpha-lipoic acid in Pheroid gel and gel that diffused into the dermis were 23.62 ug/ml and 61.06 ug/ml respectively. Aqueous solubility and log D partition coefficient of alpha-lipoic acid were determined. Inspection of the log D value of -0.78 indicated that the compound was unfavourable to penetrate the skin, whereas the aqueous solubility of 8.602 mg/ml in PBS at a temperature of 32 °C indicated favourable penetration. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2010.

Acne is a common disease characterised by follicular hyperkeratinisation, bacterial hipercolonisation as well as immune reactions and inflammation. In acne, reactive oxygen species (ROS) may be released from the damaged follicular walls, which could cause the advancement of inflammation in the pathogenesis of the disease. The topical application of antioxidants is a promising approach to support the endogenous antioxidant defence and avoid oxidative injury that may lead to acne. The skin provides a painless and patient-friendly approach for systemic drug administration. Transdermal drug delivery not only improves patient compliance, but also avoids the first-pass effect. The major hurdle to penetration of matter through the skin is provided by an outward layer of the skin, the stratum corneurm (SC). Overcoming this barrier safely and reversibly is a fundamental problem in the field of transdermal drug delivery. Alpha-lipoic acid was utilised as the cosmeceutical active and can be classified in a mixed category of compounds that lie between cosmetics and drugs. Alpha-lipoic acid and its reduced form, dihydrolipoic acid, have been described as the "universal antioxidants" because of their capacity to quench a number of free radicals in both aqueous and lipid environments, their metal-chelating properties and ability to restore other antioxidants from their inactive form. The Pheriod™ system is a new manner of drug delivery aimed at overcoming the barrier function of the skin. It consists of vesicular structures, the sizes of which vary from 200-440 nm. These vesicles, prepared from customised essential fatty acids, were found to advance the efficacy of topically administered compounds. The aim of this study was to determine whether the Pheroid™ delivery system would enhance the transdermal delivery of formulations containing alpha-lipoic acid to the target site by performing Franz cell diffusion studies over a 12 hour period, followed by tape-stripping experiments. The results of the formulations containing Pheroid™ were compared to those of the formulations without Pheroid™. Experimental determination of transdermal flux of the alpha-lipoic acid formulations revealed that Pheroid™ improved the transdermal delivery of alpha-lipoic acid. The average flux of Pheroid™ cream from 0 to 2 hours wass 58.01 ± 6.63 ug/cm2.h. The average flux of Pheroid™ gel from 4 to 12 hours was 22.18 ± 3.33 ug/cm2.h. Tape-stripping experiments proved that the concentrations of alpha-lipoic acid in Pheroid™ cream and cream that remained in the epidermis after application to the skin were 569.10 ug/ml and 764.93 ug/ml respectively. The concentrations of alpha-lipoic acid in Pheroid gel and gel that diffused into the dermis were 23.62 ug/ml and 61.06 ug/ml respectively. Aqueous solubility and log D partition coefficient of alpha-lipoic acid were determined. Inspection of the log D value of -0.78 indicated that the compound was unfavourable to penetrate the skin, whereas the aqueous solubility of 8.602 mg/ml in PBS at a temperature of 32 °C indicated favourable penetration. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2010.

Made available in DSpace on 2014-06-11T19:23:33Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-02-23Bitstream added on 2014-06-13T18:09:48Z : No. of bitstreams: 1 moraes_jdd_me_arafcf.pdf: 2965279 bytes, checksum: e4b88e85e5a2c07402cdd99a87bdd614 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Universidade Estadual Paulista (UNESP) / Diversos antioxidantes demonstram considerável efeito na prevenção do câncer por reduzir o estresse oxidativo causado por uma ampla variedade de ataques: biológicos, químicos e físicos, dentre os quais a radiação solar ultravioleta (UV) é o estresse físico ambiental descrito entre os mais freqüentes ataques que ocorrem sobre a pele, o qual está associado no desenvolvimento na maioria das doenças, incluindo o câncer. Vários componentes da dieta podem ser utilizados sozinhos ou em combinação com fármacos convencionais para prevenir doenças. Ainda, a busca por metodologias alternativas à experimentação com animais para o teste de eficácia de formas cosméticas de uso tópico é devido à pressão pública existente neste sentido, introduzida principalmente pela Comunidade Européia (93/95/EC). O presente estudo teve por objetivo avaliar a atividade do ácido alfa– lipóico em cultura de células, além do estudo de estabilidade de emulsões O/A e seu comportamento reológico. Para isto, foram utilizadas culturas de células como modelo experimental, na tentativa de desenvolver um método alternativo à experimentação com animais que poderá ser utilizado pela indústria cosmética. Foram utilizadas culturas de células HepG2 (metabolizadoras de xenobióticos) e cultura de células HaCaT (queratinócitos) / Several antioxidants show significant effect in preventing cancer by reducing oxidative stress caused by a wide variety of attacks: biological, chemical and physical agents, amongst which the sun's ultraviolet (UV) is the most physical stress environment described among the most frequent attacks that occur on the skin, which is associated with development in most diseases, including cancer. Several dietary components can be used alone or in combination with conventional drugs to prevent disease. Still, the search for alternative methods to animal testing to test the efficacy of topical cosmetic forms is due to public pressure that exists in this sense, introduced mainly by the European Union (93/95/EC). This study aims to assess the activity of alpha-lipoic acid in cultured cells, in addition to studying the stability of O / W emulsions and their rheological behavior. For this, cell cultures are used as experimental models in an attempt to develop an alternative method to animal testing that may be used by the cosmetics industry. Will be used HepG2 cell cultures (xenobiotic metabolizing) and cell culture of HaCaT (keratinocytes)

Orientador: Vera Lúcia Borges Isaac / Banca: Marcos Antonio Corrêa / Banca: Pedro Alves da Rocha Filho / Resumo: Diversos antioxidantes demonstram considerável efeito na prevenção do câncer por reduzir o estresse oxidativo causado por uma ampla variedade de ataques: biológicos, químicos e físicos, dentre os quais a radiação solar ultravioleta (UV) é o estresse físico ambiental descrito entre os mais freqüentes ataques que ocorrem sobre a pele, o qual está associado no desenvolvimento na maioria das doenças, incluindo o câncer. Vários componentes da dieta podem ser utilizados sozinhos ou em combinação com fármacos convencionais para prevenir doenças. Ainda, a busca por metodologias alternativas à experimentação com animais para o teste de eficácia de formas cosméticas de uso tópico é devido à pressão pública existente neste sentido, introduzida principalmente pela Comunidade Européia (93/95/EC). O presente estudo teve por objetivo avaliar a atividade do ácido alfa- lipóico em cultura de células, além do estudo de estabilidade de emulsões O/A e seu comportamento reológico. Para isto, foram utilizadas culturas de células como modelo experimental, na tentativa de desenvolver um método alternativo à experimentação com animais que poderá ser utilizado pela indústria cosmética. Foram utilizadas culturas de células HepG2 (metabolizadoras de xenobióticos) e cultura de células HaCaT (queratinócitos) / Abstract: Several antioxidants show significant effect in preventing cancer by reducing oxidative stress caused by a wide variety of attacks: biological, chemical and physical agents, amongst which the sun's ultraviolet (UV) is the most physical stress environment described among the most frequent attacks that occur on the skin, which is associated with development in most diseases, including cancer. Several dietary components can be used alone or in combination with conventional drugs to prevent disease. Still, the search for alternative methods to animal testing to test the efficacy of topical cosmetic forms is due to public pressure that exists in this sense, introduced mainly by the European Union (93/95/EC). This study aims to assess the activity of alpha-lipoic acid in cultured cells, in addition to studying the stability of O / W emulsions and their rheological behavior. For this, cell cultures are used as experimental models in an attempt to develop an alternative method to animal testing that may be used by the cosmetics industry. Will be used HepG2 cell cultures (xenobiotic metabolizing) and cell culture of HaCaT (keratinocytes) / Mestre

CoordenaÃÃo de AperfeÃoamento de Pessoal de NÃvel Superior / A esquizofrenia à parcialmente mimetizada pela administraÃÃo repetida de cetamina (KET), sendo este modelo sensÃvel a antipsicÃticos atÃpicos. DesequilÃbrio oxidativo à uma alteraÃÃo importante observada na esquizofrenia. O Ãcido alfa-lipÃico (ALA) à um Ãcido natural sintetizado em tecidos humanos que apresenta propriedades antioxidantes. O objetivo deste trabalho foi determinar o efeito de ALA sozinho ou associado com clozapina (CZP) na reversÃo de alteraÃÃes induzidas por KET. Camundongos machos adultos receberam KET ou soluÃÃo salina durante 7 dias. Do 8 ao 14 dia, salinas, ALA (100 mg/kg), CZP 2,5 ou 5 mg/kg foram adicionados. Sintomas do tipo esquizofrenia foram avaliados atravÃs da inibiÃÃo de prÃ-pulso (IPP) e atividade locomotora (sintomas positivos), preferÃncia social (sintomas negativos) e labirinto em y (sintomas cognitivos). AlteraÃÃes oxidativas (glutationa reduzida-GSH e peroxidaÃÃo lipÃdica-LP) e nitrito no cÃrtex prÃ-frontal (CPF), hipocampo (HC) e corpo estriado (CE); e fator neurotrÃfico derivado do cÃrebro (BDNF) no CPF tambÃm foram abordadas. Cetamina causou dÃficits no IPP, memÃria de trabalho, interaÃÃo social; e tambÃm causou hiperlocomoÃÃo. AlÃm disso, diminuiu GSH, nitrito e BDNF; e aumentou LP. ALA sozinho reverteu alteraÃÃes comportamentais induzidas por KET. TambÃm reverteu a diminuiÃÃo de GSH no HC, BDNF e o aumento da LP (CPF, HC e CE). A combinaÃÃo de CZP 2,5 + ALA reverteu o comportamento e alguns parÃmetros neuroquÃmicos. No entanto, CZP 5 + ALA causou deficiÃncia motora. No geral, ALA parece apresentar um perfil semelhante aos antipsicÃtico atÃpicos revertendo os sintomas positivos e negativos induzidos pela KET. O mecanismo envolve parcialmente aÃÃo antioxidante, neurotrÃfica e as vias nitrÃrgicas. A combinaÃÃo com CZP apresentaram resultados positivos, principalmente, com a dose mais baixa. / Schizophrenia is partially mimicked by the repeated administration of ketamine (KET) being this model sensitive to atypical antipsychotics. Oxidative imbalance is an important alteration seen in schizophrenia. Alpha-lipoic acid (ALA) is a natural acid synthesized in human tissues presenting antioxidant properties. Herein we aimed to determine the effect of ALA alone or combined with clozapine (CZP) in the reversal of KET-induced alterations. Adult male mice received KET or saline during 7 days. From the 8 th to 14th days, saline, ALA (100 mg/kg), CZP 2.5 or 5 mg/kg were added. Schizophrenia-like symptoms were evaluated by prepulse inhibition (PPI) of the startle and locomotor activity (positive - like), social preference (negative - like) and Y maze (cognitive - like). Oxidative alterations (reduced glutathione - GSH and lipid peroxidation - LP) and nitrite in the prefrontal cortex (CPF), hippocampus (HC) and striatum (ST) and BDNF in the CPF were also addressed. Ketamine caused deficits in PPI, working memory, social interaction together with hyperlocomotion. Additionally, decreases in GSH, nitrite and BDNF and increases in LP were observed. ALA alone reversed KET - induced behavioral alterations. It also reversed the decreases in GSH in the HC, BDNF and increase in LP (CPF, HC and ST). The combination CZP 2.5 + ALA reversed behavioral and some neurochemical parameters. However, CZP 5 + ALA caused motor impairment. Overall, ALA seems to present an atypical antipsychotic-like profile reversing KET - induced positive and negative - like symptoms. The mechanism partially involves antioxidant, neurotrophic and nitrergic pathways. The combination with CZP presented positive results mainly with the lower dose.

Background: Neurite outgrowth is an important aspect of neuronal plasticity and regeneration after neuronal injury. Alpha-lipoic acid (LA) has been used as a therapeutic approach for a variety of neural disorders. We recently reported that LA prevents local anesthetics-induced neurite loss. In this study, we hypothesized that LA administration promotes neurite outgrowth. Methods: To test our hypothesis, we treated mouse neuroblastoma N2a cells and primary neurons with LA. Neurite outgrowth was evaluated by examination of morphological changes and by immunocytochemistry for α-tubulin-3. ROS production was examined, as were the phosphorylation levels of ERK and Akt. In separate experiments, we determined the effects of the inhibition of ERK or PI3K/Akt as well as ROS production on LA-induced neurite outgrowth. Results: LA promoted significantly neurite outgrowth in a time- and concentration-dependent manner. LA stimulation significantly increased the phosphorylation levels of both Akt and ERK and transiently induced ROS production. PI3K/Akt inhibition did not affect LA-induced neurite outgrowth. However, the inhibition of ERK activation completely abolished LA-induced neurite outgrowth. Importantly, the prevention of ROS production by antioxidants attenuated LA-stimulated ERK activation and completely abolished LA-promoted neurite outgrowth. Conclusion: Our data suggest that LA stimulates neurite outgrowth through the activation of ERK signaling, an effect mediated through a ROS-dependent mechanism. This article is part of a Special Issue entitled: 11th European Symposium on Calcium.

A síndrome de ardência bucal (SAB) é uma condição crônica, caracterizada por sensação de ardor bucal sem alterações clinicamente detectáveis. Afeta predominantemente mulheres no período pós-menopausa e sua terapêutica ainda não está estabelecida. Pelo menos dois terços destes pacientes apresentam queixa subjetiva de disgeusia como sintoma secundário associado. O objetivo deste estudo foi avaliar a efetividade do ácido alfa lipóico, como alternativa terapêutica no controle dos sintomas da SAB, por meio de um estudo duplo-cego cruzado, placebocontrolado. Foi realizada também uma investigação da função gustatória destes pacientes, pela aplicação de teste objetivo de reconhecimento dos quatro sabores básicos. Foram incluídos trinta e cinco pacientes (31 mulheres, 4 homens, média de idade 63,1 anos, variação 36-78 anos) e 31 pacientes completaram o estudo terapêutico. Os pacientes foram randomizados para dois ciclos de tratamento um com ácido alfa lipóico e um com placebo, ambos administrados em cápsulas idênticas. Estes ciclos de tratamento foram separados por um período de washout de 20 dias. O sintoma de ardor bucal e a resposta terapêutica foram avaliadas utilizando uma escala visual de sintomatologia (EVS) numérica de 10 pontos antes do início e ao término de cada ciclo e pelo efeito global percebido (EGP), usando uma escala de 5 pontos ao término de cada ciclo de tratamento. O nível de redução sobre o sintoma de ardor avaliado pela EVS foi estatisticamente significante para ambos os tratamentos (31,15% com ácido alfa lipoico e 34,09% ao término do do primeiro ciclo; 12,55% para ácido alfa lipóico e 28,09% para placebo ao término do segundo ciclo). Considerando-se os resultados de EGP dos dois ciclos, 22 pacientes reportaram pelo menos alguma melhora após utilizarem ácido alfa lipóico e 23 pacientes após utilizarem placebo. A comparação dos scores obtidos dos dois ciclos pelo teste t falharam em demonstrar efetividade para ácido alfa lipóico sobre placebo. A queixa subjetiva de disgeusia esteve associada à de ardor em 60% dos casos. No teste objetivo de paladar foram verificados erros de identificação dos sabores básicos em 35,23% das amostras para o amargo, 20% para o azedo, 20% para o doce e 19% para salgado, estes erros foram observados também entre pacientes que não apresentavam a queixa subjetiva de disgeusia. Apenas 5 pacientes (14,28%) conseguiram identificar corretamente os quatro sabores básicos. A maior parte dos erros de identificação ocorreu para o sabor amargo e em baixas concentrações. A análise dos dados obtidos nos permitiu concluir que o ácido alfa lipóico não foi efetivo no controle dos sintomas associados à síndrome de ardência bucal e que existe uma associação da síndrome com as alterações da função gustatória. / The burning mouth syndrome is a chronic condition caractherized by an oral burning sensation without clinical signs. Post menopausean women are mostly affected and the therapy is not stablished. Two thirds or more of these patients shown dysgeusia as a secondary associate complaint. The purpose of this study was to evaluate the effectiveness of alpha lipoic acid in the management of burning mouth syndrome symptoms through a randomized double-blind placebo-controlled crossover trial. In addiction, a preliminary evaluation of taste function was performed by objective test to recognition of the four basic flavors. Thirty-five patients (31 women, 4 men, median age 63.1 years, range 36-78) were included and 31 completed the therapeutic study. The patients were randomized for two cycles of treatmentone with alpha lipoic acid and one with placebo, both administered in identical capsules. These cycles were separated by a washout period of 20 days. The oral symptoms and the treatment response were assessed using a 10 point numerical visual analogue scale (VAS) before and after each cycle and the global perceived effect (GPE) score, using a 5- point scale at the end of each treatment cycle. The level of burning reduction assessed by VAS was significant for both treatments (31.15% with ALA treatment and 34.09% with placebo after first cycle and 12.55% for ALA and 28.09% for placebo after second cycle). Considering the results of GPE in the two cycles together, twenty-two patients reported at least some improvement after alpha lipoic acid use and twenty-three patients after placebo. Comparison of the oral assessment scores of the two cycles with t test failed to demonstrate effectiveness for alpha lipoic acid over placebo. Dysgeusia was associated with burning mouth in 60% of the cases. In the objective taste evaluation, identification errors were observed in 35,23% of the samples for bitter, 20% for sour, 20% for sweet and 19% for salty. Moreover, these errors were observed among patients whose not complain of dysgeusia. Only 5 patients (14,28%) had correct identification of four basic flavors. Most of identifications errors were observed in bitter taste and in lower concentrations. We concluded that alpha lipoic acid was not effective in the control of burning mouth syndrome symptoms in this study and there is a relation of taste disfunction with the syndrome.

Made available in DSpace on 2014-12-17T14:25:21Z (GMT). No. of bitstreams: 1 AlyneSP_DISSERT.pdf: 2677800 bytes, checksum: ae0cc2c34a761b6f5adc64dba8b50ed8 (MD5) Previous issue date: 2013-07-01 / Alpha-lipoic acid (ALA) is a potent antioxidant with favourable anti-inflammatory, metabolic and endothelial effects, and has been widely investigated due to its potential against cardiovascular risk factors. This study aimed to evaluate the effect of oral ALA supplementation on oxidative stress biomarkers, inflammation and cardiovascular risk factors in patients with hypertension. This is a double-blind placebo-controlled randomized clinical trial, where the intervention was evaluated prospectively comparing results in both groups. The sample consisted of 64 hypertensive patients who were randomly distributed into ALA group (n = 32), receiving 600 mg / day ALA for twelve weeks and control group (n = 32), receiving placebo for the same period. The following parameters were evaluated before and after intervention: lipid peroxidation, content of reduced glutathione (GSH), enzymatic activities of glutathione peroxidase (GPx) and superoxide dismustase, ultrasensitive C-reactive protein (hs-CRP), triglycerides, total cholesterol and fractions, fasting glucose and anthropometric indicators. There was a statistically significant reduction (p <0.05) in serum concentrations of total cholesterol, very low density lipoprotein (VLDL), high density lipoprotein (HDL), triglycerides and blood glucose. There was a reduction in body weight and waist, abdominal and hip circumferences in the group that received ALA. In addition, there was a statistically significant increase (p <0.05) in the contents of reduced glutathione (GSH) and glutathione peroxidase (GPx) in the group receiving ALA. Oral administration of ALA appears to be a valuable adjuvant therapy, which may contribute to decrease the damage caused by oxidative stress and other risk factors associated with the atherosclerotic process / O ?cido alfa-lip?ico (AAL) ? um potente antioxidante, com favor?veis efeitos antiinflamat?rios, metab?licos e endoteliais, assim vem sendo intensamente investigado no combate aos fatores de risco cardiovascular. O estudo teve como objetivo avaliar o efeito da suplementa??o oral do AAL sobre biomarcadores de estresse oxidativo, inflama??o e fatores de risco cardiovascular em portadores de hipertens?o. Trata-se de um estudo cl?nico randomizado, duplo-cego e controlado com placebo, no qual a interven??o foi avaliada prospectivamente, comparando os resultados nos dois grupos. A amostra foi constitu?da por 64 indiv?duos hipertensos que foram distribu?dos aleatoriamente em grupo AAL (n=32), que recebeu 600 mg/dia de AAL por doze semanas e grupo controle (n=32), que recebeu o placebo pelo mesmo per?odo. Foram avaliados antes e depois da interven??o: subst?ncias reativas ao ?cido tiobarbit?rico (SRAT), conte?do da glutationa reduzida (GSH); atividades enzim?ticas da glutationa peroxidase (GPx) e da super?xido dismustase; prote?na C reativa (PCR-us); triglicer?deos, colesterol total e fra??es; glicemia de jejum; e indicadores antropom?tricos. Observou-se uma redu??o estatisticamente significativa (p < 0.05) nas concentra??es s?ricas de colesterol total, lipoprote?na de muita baixa densidade (VLDL), lipoprote?na de alta densidade (HDL), triglicer?deos e glicose. No grupo AAL Tamb?m houveram redu??es do peso corporal e das circunfer?ncias abdominais, da cintura e do quadril. Ainda, observou-se um aumento estatisticamente significativo (p < 0.05) do conteudo de glutationa reduzida (GSH) e da atividade da glutationa peroxidase (GPx) no grupo que recebeu o AAL. A administra??o oral do AAL mostrou-se como um valioso adjuvante terap?utico, que pode contribuir com a diminui??o dos danos causados pelo estresse oxidativo e outros fatores de risco cardiovascular que est?o associados com o processo ateroscler?tico / 2019-11-09

A síndrome de ardência bucal (SAB) é uma condição crônica, caracterizada por sensação de ardor bucal sem alterações clinicamente detectáveis. Afeta predominantemente mulheres no período pós-menopausa e sua terapêutica ainda não está estabelecida. Pelo menos dois terços destes pacientes apresentam queixa subjetiva de disgeusia como sintoma secundário associado. O objetivo deste estudo foi avaliar a efetividade do ácido alfa lipóico, como alternativa terapêutica no controle dos sintomas da SAB, por meio de um estudo duplo-cego cruzado, placebocontrolado. Foi realizada também uma investigação da função gustatória destes pacientes, pela aplicação de teste objetivo de reconhecimento dos quatro sabores básicos. Foram incluídos trinta e cinco pacientes (31 mulheres, 4 homens, média de idade 63,1 anos, variação 36-78 anos) e 31 pacientes completaram o estudo terapêutico. Os pacientes foram randomizados para dois ciclos de tratamento um com ácido alfa lipóico e um com placebo, ambos administrados em cápsulas idênticas. Estes ciclos de tratamento foram separados por um período de washout de 20 dias. O sintoma de ardor bucal e a resposta terapêutica foram avaliadas utilizando uma escala visual de sintomatologia (EVS) numérica de 10 pontos antes do início e ao término de cada ciclo e pelo efeito global percebido (EGP), usando uma escala de 5 pontos ao término de cada ciclo de tratamento. O nível de redução sobre o sintoma de ardor avaliado pela EVS foi estatisticamente significante para ambos os tratamentos (31,15% com ácido alfa lipoico e 34,09% ao término do do primeiro ciclo; 12,55% para ácido alfa lipóico e 28,09% para placebo ao término do segundo ciclo). Considerando-se os resultados de EGP dos dois ciclos, 22 pacientes reportaram pelo menos alguma melhora após utilizarem ácido alfa lipóico e 23 pacientes após utilizarem placebo. A comparação dos scores obtidos dos dois ciclos pelo teste t falharam em demonstrar efetividade para ácido alfa lipóico sobre placebo. A queixa subjetiva de disgeusia esteve associada à de ardor em 60% dos casos. No teste objetivo de paladar foram verificados erros de identificação dos sabores básicos em 35,23% das amostras para o amargo, 20% para o azedo, 20% para o doce e 19% para salgado, estes erros foram observados também entre pacientes que não apresentavam a queixa subjetiva de disgeusia. Apenas 5 pacientes (14,28%) conseguiram identificar corretamente os quatro sabores básicos. A maior parte dos erros de identificação ocorreu para o sabor amargo e em baixas concentrações. A análise dos dados obtidos nos permitiu concluir que o ácido alfa lipóico não foi efetivo no controle dos sintomas associados à síndrome de ardência bucal e que existe uma associação da síndrome com as alterações da função gustatória. / The burning mouth syndrome is a chronic condition caractherized by an oral burning sensation without clinical signs. Post menopausean women are mostly affected and the therapy is not stablished. Two thirds or more of these patients shown dysgeusia as a secondary associate complaint. The purpose of this study was to evaluate the effectiveness of alpha lipoic acid in the management of burning mouth syndrome symptoms through a randomized double-blind placebo-controlled crossover trial. In addiction, a preliminary evaluation of taste function was performed by objective test to recognition of the four basic flavors. Thirty-five patients (31 women, 4 men, median age 63.1 years, range 36-78) were included and 31 completed the therapeutic study. The patients were randomized for two cycles of treatmentone with alpha lipoic acid and one with placebo, both administered in identical capsules. These cycles were separated by a washout period of 20 days. The oral symptoms and the treatment response were assessed using a 10 point numerical visual analogue scale (VAS) before and after each cycle and the global perceived effect (GPE) score, using a 5- point scale at the end of each treatment cycle. The level of burning reduction assessed by VAS was significant for both treatments (31.15% with ALA treatment and 34.09% with placebo after first cycle and 12.55% for ALA and 28.09% for placebo after second cycle). Considering the results of GPE in the two cycles together, twenty-two patients reported at least some improvement after alpha lipoic acid use and twenty-three patients after placebo. Comparison of the oral assessment scores of the two cycles with t test failed to demonstrate effectiveness for alpha lipoic acid over placebo. Dysgeusia was associated with burning mouth in 60% of the cases. In the objective taste evaluation, identification errors were observed in 35,23% of the samples for bitter, 20% for sour, 20% for sweet and 19% for salty. Moreover, these errors were observed among patients whose not complain of dysgeusia. Only 5 patients (14,28%) had correct identification of four basic flavors. Most of identifications errors were observed in bitter taste and in lower concentrations. We concluded that alpha lipoic acid was not effective in the control of burning mouth syndrome symptoms in this study and there is a relation of taste disfunction with the syndrome.

No description available.